BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 15, 2011
View Archived Issues
Experiments reveal new target and agents to treat autosomal dominant polycystic kidney disease
Read More
New PAI-1 inhibitor ameliorates experimental collapsing focal segmental glomerulosclerosis
Read More
Effect of hepatic impairment on single-dose pharmacokinetics of daclatasvir investigated
Read More
Novel voltage-gated K(V)7 potassium channel modulator has anticonvulsant activity
Read More
Cancer therapy Lipotecan advances through first-in-human trial
Read More
New arginase inhibitors developed at Mars
Read More
Scientists at Roche prepare novel vasopressin V1A receptor antagonists
Read More
Pierre Fabre presents new acyl-CoA desaturase inhibitors
Read More
U.S. universities synthesize novel HIF-1 inhibitors
Read More
Avaxia Biologics raises funds to develop oral antibodies for inflammatory bowel disease
Read More
New Rho-associated protein kinase inhibitors patented
Read More
Anavex completes phase I trial of ANAVEX 2-73
Read More
FDA approves first umbilical cord-derived stem cell product for transplantation
Read More
Phase III trial of vorapaxar does not meet primary endpoint
Read More
Dyax provides update on European regulatory status of ecallantide
Read More
Merck & Co. reports pipeline progress
Read More
Eli Lilly and Boehringer Ingelheim begin phase III trials of LY-2605541
Read More
Avraham Pharmaceuticals raises funds to advance development of ladostigil
Read More
Novartis reports first data from 3-year phase III SMC-021 study
Read More
Merck Sharp & Dohme withdraws MAA for fixed-dose combination of sitagliptin and pioglitazone
Read More
Shionogi recaps progress made in second quarter of fiscal year 2011
Read More
FDA grants priority review to NeurogesX's sNDA for Qutenza
Read More
Phase IIa study of Theravance LAMA meets primary endpoint
Read More
FDA and EMA accept Astellas' submissions for mirabegron
Read More
Gilead Sciences presents highlights of third quarter 2011
Read More
Bend Research to provide Merck & Co. with drug delivery technology
Read More
Kyowa Hakko Kirin launches new formulation of second-generation antihistamine in Japan
Read More
